TNO-6 has no effect in gastrointestinal cancer: N-acetyl-glucosaminidase shows renal damage.
Twenty-five patients, 16 with gastric cancer and nine with colonic cancer, received TNO-6 30 mg m-2 every four weeks. No objective tumour response was recorded. Nausea and vomiting occurred in 21 patients and was severe in 17. Severe marrow suppression developed in five patients. Renal function was unaffected in all but one patient who developed renal failure, probably as a result of septicaemia. However, the renal tubular enzyme N-acetyl-beta-D-glucosaminidase was measured in six patients and showed a rise in all. In this study TNO-6 had no anti-tumour activity in gastrointestinal malignancy, but produced significant renal tubular damage.
Cunningham
D
D
Soukop
M
M
Gilchrist
N L
NL
Forrest
G J
GJ
Carter
D C
DC
McArdle
C S
CS
Kaye
S B
SB
Dobbie
J W
JW
Smith
M
M
D000118:Acetylglucosaminidase / Q000652:urine; D000230:Adenocarcinoma / Q000188:drug therapy*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000188:drug therapy*
D009944:Organoplatinum Compounds; D000118:Acetylglucosaminidase; C040757:spiroplatin